Key Points
- Insider sale: Gilead CFO Andrew Dickinson sold 3,000 shares at an average price of $154.43 for $463,290 (SEC Form 4), and the report also notes a larger 28,000‑share sale by Johanna Mercier that may weigh on sentiment.
- Quarterly beat and guidance: Gilead beat Q4 estimates with $1.86 EPS and $7.93B revenue, set FY2026 guidance of $8.45–$8.85 EPS, and raised its quarterly dividend to $0.82 (annualized $3.28, ~2.1% yield).
- Analyst and institutional view: Analysts are largely positive (23 Buys, 3 Holds) with a consensus target around $152.96 and several firms raising targets (as high as $170), while institutional investors hold about 83.7% of the stock.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company's stock, valued at $25,910,110.97. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Gilead Sciences Stock Down 1.6%
GILD stock opened at $152.74 on Thursday. The firm has a 50-day simple moving average of $132.29 and a 200-day simple moving average of $123.18. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $189.50 billion, a P/E ratio of 22.56, a P/E/G ratio of 2.06 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences's dividend payout ratio (DPR) is currently 46.68%.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, January 26th. Mizuho boosted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an "outperform" rating in a research note on Friday, November 21st. HSBC lifted their target price on Gilead Sciences from $110.00 to $133.00 and gave the company a "hold" rating in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. Finally, TD Cowen boosted their price objective on Gilead Sciences from $145.00 to $160.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $152.96.
Get Our Latest Research Report on Gilead Sciences
Institutional Investors Weigh In On Gilead Sciences
Several hedge funds have recently made changes to their positions in the business. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $215,000. Sivia Capital Partners LLC lifted its stake in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after buying an additional 602 shares in the last quarter. Princeton Global Asset Management LLC increased its position in Gilead Sciences by 58.2% during the second quarter. Princeton Global Asset Management LLC now owns 791 shares of the biopharmaceutical company's stock worth $88,000 after buying an additional 291 shares in the last quarter. Finally, Drive Wealth Management LLC boosted its stake in shares of Gilead Sciences by 28.9% during the 2nd quarter. Drive Wealth Management LLC now owns 4,672 shares of the biopharmaceutical company's stock worth $518,000 after purchasing an additional 1,048 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Key Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Rothschild & Co Redburn raised its price target on GILD to $170 and maintained a Buy rating — this adds upside perception (~11% above recent price) and supports bullish analyst-driven flows. Rothschild PT Raise
- Positive Sentiment: News highlighting Gilead’s HIV franchise progress and a Yescarta label shift is reframing the investment thesis toward durable HIV revenue plus potential CAR-T positioning — supportive for medium-term growth expectations. HIV & Yescarta Article
- Neutral Sentiment: Maxim Group’s Michael Okunewitch reiterated a Hold rating, noting strong HIV growth may be largely priced in and diversification still limited — a cautious tone that tempers upside. TipRanks / Hold Rating
- Neutral Sentiment: Benzinga’s retrospective on 5‑year returns (what $1,000 then would be worth today) is informational for retail investors but unlikely to move price materially by itself. Benzinga Performance Piece
- Neutral Sentiment: Analyst Q&A coverage from Gilead’s Q4 earnings call highlights issues analysts want answered (pipeline timing, margins, guidance drivers). Useful context for investors but mixed in directional impact. Q4 Earnings Call Questions
- Negative Sentiment: Insider selling: CFO Andrew D. Dickinson sold 3,000 shares at ~$$154.43 (SEC filing). Large or leadership insider sales can pressure sentiment even when scheduled/known. CFO Form 4
- Negative Sentiment: Significant insider sale by Johanna Mercier: 28,000 shares sold at ~$$154.44 (18.9% reduction in her holding) — a large single insider transaction that may weigh on investor confidence. Mercier Form 4
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
